Marinomed Biotech AG Logo

Marinomed Biotech AG

Develops virus-blocking products & immunology therapies via proprietary technology platforms.

MARI | VI

Overview

Corporate Details

ISIN(s):
ATMARINOMED6
LEI:
529900GN3B1EN80XF405
Country:
Austria
Address:
Hovengasse 25, 2100 Korneuburg
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Marinomed Biotech AG is a science-based biopharmaceutical company that develops innovative therapies for diseases in virology and immunology. The company leverages two proprietary technology platforms: Carragelose®, a virus-blocking compound used in globally marketed nasal sprays and lozenges, and Marinosolv®, a technology platform that enhances the solubility of poorly soluble compounds to develop new treatments for various immunological conditions. Marinomed's business model encompasses in-house development of medicinal products and medical devices, as well as strategic partnerships to commercialize its pipeline and technologies. The company focuses on addressing conditions with limited or no effective treatment options, particularly in respiratory and autoreactive immune disorders.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-31 10:01
Declaration of Voting Results & Voting Rights Announcements
EQS-NVR: Marinomed Biotech AG: Release according to Article 135, Section 1 Börs…
English 16.5 KB
2025-10-31 10:01
Declaration of Voting Results & Voting Rights Announcements
EQS-NVR: Marinomed Biotech AG: Veröffentlichung der Gesamtstimmrechte nach § 13…
German 17.0 KB
2025-10-31 10:00
Declaration of Voting Results & Voting Rights Announcements
Release according to Article 135, Section 1 BorseG with the objective of Europe…
English 3.6 KB
2025-10-06 14:58
Regulatory News Service
EQS-Adhoc: Marinomed Biotech AG begins reviewing strategic options for the Mari…
English 34.6 KB
2025-10-06 14:58
M&A Activity
EQS-Adhoc: Marinomed Biotech AG startet Prüfung strategischer Optionen für die …
German 36.4 KB
2025-10-06 14:56
Regulatory News Service
Marinomed Biotech AG begins reviewing strategic options for the Marinosolv plat…
English 11.1 KB
2025-09-17 13:48
Earnings Release
Marinomed Biotech AG announces results for the first half year of 2025
English 10.6 KB
2025-09-17 13:42
Interim Report
EQS-AFR: Marinomed Biotech AG: Release of a Financial report
English 3.4 MB
2025-09-17 13:42
Interim Report
EQS-AFR: Marinomed Biotech AG: Bekanntmachung über die Veröffentlichung eines F…
German 3.5 MB
2025-09-16 15:24
Share Issue/Capital Change
EQS-Adhoc: Marinomed Biotech AG resolves capital increase excluding statutory s…
English 31.7 KB
2025-09-16 15:24
Share Issue/Capital Change
EQS-Adhoc: Marinomed Biotech AG beschließt Kapitalerhöhung unter Bezugsrechtsau…
German 33.7 KB
2025-09-16 15:22
Share Issue/Capital Change
Marinomed Biotech AG resolves capital increase excluding statutory subscription…
English 8.0 KB
2025-09-02 09:18
Pre-Annual General Meeting Information
EQS-AGM: Marinomed Biotech AG: Convening of an Extraordinary General Meeting fo…
English 51.6 KB
2025-09-02 09:17
Pre-Annual General Meeting Information
EQS-HV: Marinomed Biotech AG: Einberufung einer außerordentlichen Hauptversamml…
German 50.1 KB
2025-09-02 09:16
Pre-Annual General Meeting Information
Marinomed Biotech AG: Convening of an Extraordinary General Meeting for Tuesday…
English 21.9 KB

Automate Your Workflow. Get a real-time feed of all Marinomed Biotech AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Marinomed Biotech AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Marinomed Biotech AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Sionna Therapeutics, Inc. Logo
Developing novel NBD1 stabilizers and CFTR modulators to treat cystic fibrosis.
United States of America SION
SK biopharmaceuticals Co., Ltd. Logo
Develops and commercializes CNS and oncology therapies for global markets, focusing on the U.S.
South Korea 326030
SK Bioscience Co.,Ltd Logo
A global biotech firm developing vaccines for diseases like COVID-19, influenza, and shingles.
South Korea 302440
Skye Bioscience, Inc. Logo
Clinical-stage biotech developing a CB1-inhibiting antibody for obesity and metabolic diseases.
United States of America SKYE
SoftOx Solutions AS Logo
Develops non-toxic, AMR-safe antimicrobials for wound care, disinfection & airway infections.
Norway SOFTX
Solasia Pharma K.K. Logo
In-licenses and commercializes oncology treatments and supportive care products in Asia.
Japan 4597
SOLENO THERAPEUTICS INC Logo
Develops novel therapeutics for rare diseases like Prader-Willi syndrome.
United States of America SLNO
Sol-Gel Technologies Ltd. Logo
Develops and commercializes topical dermatology drugs for acne, rosacea, and rare skin conditions.
United States of America SLGL
Solid Biosciences Inc. Logo
Advancing gene therapies and technologies for rare neuromuscular and cardiac diseases.
United States of America SLDB
SOLIGENIX, INC. Logo
Late-stage biopharma developing treatments for rare diseases and public health threats.
United States of America SNGX

Talk to a Data Expert

Have a question? We'll get back to you promptly.